Authors

George Kim, MD, 21st Century Oncology

George Kim, MD, University of Florida Health Oncology

George N. Ioannou, MD

Latest:

Dr. Ioannou on Treatment Options in Hepatocellular Carcinoma

George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses the best treatment options for patients with hepatocellular carcinoma.

George P. Kim, MD

Latest:

Dr. Kim on PRODIGE 37 in Pancreatic Cancer

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

George P. Kim, MD, 21st Century Oncology

George R. Blumenschein, MD

Latest:

Dr. Blumenschein on Immunotherapy Combinations in NSCLC

George R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).

George R. Simon, MD

Latest:

Dr Simon on the ALK Inhibitor Selection Process in ALK+ NSCLC

George R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.

George R. Simon, MD, FACP, FCCP

Latest:

Dr. Simon on the Impact of Immunotherapy Agents in NSCLC

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

George Sledge, Jr., MD

Latest:

Dr. Sledge on Genomic Sequencing in Patients With Breast Cancer

George Sledge, Jr., MD, discusses the benefit to the cost of genomic sequencing decreasing overtime.

George Somlo, MD

Latest:

Dr. George Somlo on Treatment Considerations for Multiple Myeloma

George Somlo, MD, medical oncologist, City of Hope, discusses treatment considerations in multiple myeloma.

George W. Sledge Jr, MD

Latest:

Looking for a Therapeutic Edge Among CDK Inhibitors

Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.

Georgia L. Wiesner, MD, MS

Latest:

Dr. Wiesner on Benefits of Genetic Testing in Colorectal Cancer

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

Georgina Long, BSc, MBBS, FRACP, Melanoma Institute of Australia

Georgina Long, BSc, PhD, MBBS, FRACP

Latest:

Dr Long on Unmet Needs in BRAF-Mutant Melanoma

Georgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial.

Georgina Long, MD, Melanoma Institute of Australia

Georgina Long, MD, PhD, Melanoma Institute of Australia at the University of Sydney

Georgina V. Long, BSc, PhD, MBBS

Latest:

Dr. Long on Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.

Georgina V. Long, BSc, PhD, MBBS, FRACP

Latest:

Dr. Long on Rationale for Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma who have brain metastases.

Gerald J. Berry, MD, Stanford University

Gerald S. Falchook, MD

Latest:

Dr. Falchook on TRK Alterations in Lung Cancer

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses TRK alterations in lung cancer.